An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

Completed · Not applicable

Conditions studied: HIV Infections

In brief

To allow, on a compassionate use basis, zalcitabine (ddC) for pediatric patients with symptomatic HIV disease who have failed treatment or who are intolerant to zidovudine (AZT), or who have completed other ddC protocols, or who are ineligible for ongoing clinical trials.

Key facts

Study ID

NCT00002118

Run by

Hoffmann-La Roche

People needed

600

Last updated by the study team

2005-06-24

Who can join

Age: 0 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Symptomatic HIV infection.
• Failure on or intolerance to AZT monotherapy OR completed other ddC protocols OR been ineligible for other ongoing clinical trials.
• Consent of parent or guardian required.
• Note:
• Patients who do not meet the eligibility requirements may discuss their cases with the medical monitor.

Where it is running

• Hoffmann - La Roche Inc — Nutley, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.